Stock comparison
Eli Lilly
Teva Pharmaceutical Industries Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
TEVA
Teva Pharmaceutical Industries Limited
Market cap
$39.67B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | TEVA | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 46D | LLY |
| Benjamin Graham | 86A | 60D | LLY |
| Philip Fisher | 86A | 59C | LLY |
| Peter Lynch | 74B | 53C | LLY |
| Joel Greenblatt | 78C | 49D | LLY |
| Charlie Munger | 85A | 50D | LLY |
| Terry Smith | 77C | 41D | LLY |
Side-by-side metrics
| Metric | LLY | TEVA |
|---|---|---|
| Market cap | $1T | $39.67B |
| P/E (TTM) | 36.6x | 25.4x |
| EV/EBIT | 34.1x | 24.8x |
| ROIC (TTM) | 32.06% | 11.49% |
| Gross margin | 83.51% | 51.98% |
| Net margin | 34.98% | 9.03% |
| Revenue CAGR 5y | 23.17% | 2.1% |
| EPS CAGR 5y | 40.81% | 34.13% |
| Debt / Equity | 1.4x | 2.1x |
| Dividend yield | 0.62% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $39.67B+96%
- Revenue CAGR 5y23.17%vs 2.1%+91%
- Net margin34.98%vs 9.03%+74%
TEVA leads on
- P/E (TTM)25.4xvs 36.6x+31%
- EV/EBIT24.8xvs 34.1x+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.